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Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) induces multiple signal transduction pathways during latent EBV
infection via its C-terminal activating region 1 (CTAR1), CTAR2, and the less-studied CTAR3. One mechanism by which LMP1
regulates cellular activation is through the induction of protein posttranslational modifications, including phosphorylation and
ubiquitination. We recently documented that LMP1 induces a third major protein modification by physically interacting with
the SUMO-conjugating enzyme Ubc9 through CTAR3 and inducing the sumoylation of cellular proteins in latently infected
cells. We have now identified a specific target of LMP1-induced sumoylation, interferon regulatory factor 7 (IRF7). We hypothe-
size that during EBV latency, LMP1 induces the sumoylation of IRF7, limiting its transcriptional activity and modulating the
activation of innate immune responses. Our data show that endogenously sumoylated IRF7 is detected in latently infected EBV
lymphoblastoid cell lines. LMP1 expression coincided with increased sumoylation of IRF7 in a CTAR3-dependent manner. Addi-
tional experiments show that LMP1 CTAR3-induced sumoylation regulates the expression and function of IRF7 by decreasing
its turnover, increasing its nuclear retention, decreasing its DNA binding, and limiting its transcriptional activation. Finally, we
identified that IRF7 is sumoylated at lysine 452. These data demonstrate that LMP1 CTAR3 does in fact function in intracellular
signaling, leading to biologic effects. We propose that CTAR3 is an important signaling region of LMP1 that regulates protein
function by sumoylation. We have shown specifically that LMP1 CTAR3, in cooperation with CTAR2, can limit the ability of
IRF7 to induce innate immune responses by inducing the sumoylation of IRF7.
Epstein-Barr virus (EBV) is a ubiquitous gammaherpesvirusthat infects more than 90% of the world’s population and es-
tablishes a lifelong infection within the host. Latent EBV infection
is associated with several lymphoid tumors, including posttrans-
plant lymphoproliferative disorder (PTLD), and AIDS-associated
central nervous system (CNS) lymphomas (32, 33), which are
associated with type III EBV latency. This form of latency is ob-
served in lymphoblastoid cell lines (LCLs), which are established
following EBV infection of primary B cells and exhibit sustained
cellular proliferation and survival due to the constitutive activa-
tion of cellular signaling pathways. The main viral protein impor-
tant in regulating these signal transduction events is latent mem-
brane protein 1 (LMP1), an integral membrane signaling protein
that mimics the tumor necrosis factor receptor family members,
such as CD40, with the exception that its activation is ligand in-
dependent and it is constitutively active (22). LMP1 activates mul-
tiple signal transduction events via its C-terminal region (3, 9, 22;
A. Kieser, presented at the 13th Biennial Conference of the Inter-
national Association for Research on Epstein-Barr Virus and As-
sociated Diseases, Guangzhou, China, 2008). One signaling path-
way of continuing interest in our laboratory is the regulation of
interferon regulatory factor 7 (IRF7) by LMP1.
IRFs are a family of transcription factors that regulate inter-
feron responses, and IRFs have also been implicated in the regu-
lation of cell growth and differentiation, apoptosis, and oncogen-
esis (31, 34). The N-terminal regions of IRFs contain the
conserved DNA-binding domain (DBD), allowing the IRFs to
bind to consensus motifs found in interferon (IFN)-stimulated
response elements (ISREs), including promoters of type I IFNs.
The C-terminal regions of the IRFs are much more variable, re-
sulting in distinct IRF-protein interactions, and guide the various
functions of IRFs and the specificity of their interactions.
Of all the IRFs, IRF7 and IRF3 are key regulators of the expres-
sion of type I IFNs, which include alpha IFN (IFN-) and beta IFN
(IFN-) (11–13, 34, 36, 46). While IRF3 is considered to be re-
sponsible for the early phase of type I IFN induction, IRF7 is now
understood to be the master regulator of all type I IFN-dependent
immune responses (13). Our laboratory identified IRF7 in a
search for a regulator of the EBV nuclear antigen 1 (EBNA-1)
promoter used in type I latency: Qp, to which IRF7 binds (31, 45).
We also found that IRF7 binds to and activates the LMP1 pro-
moter (28, 29). Since then, IRF7 has been recognized as having a
major role in the control of the host immune response, including
the induction of IFN- through cooperation with STAT1 and
IRF1 (8, 12, 13). In lymphoid cells, IRF7 is constitutively expressed
at low levels. Increased expression can be induced by various stim-
uli, including EBV LMP1 (31, 46). In addition to inducing IRF7
expression, LMP1 regulates the function of IRF7 by inducing
posttranslational modifications of this protein (14, 27, 42, 43).
Two major posttranslational modifications of IRF7 that we
have examined are phosphorylation and ubiquitination. LMP1
induces the phosphorylation and K63-linked ubiquitination of
IRF7, resulting in its nuclear translocation and increased tran-
scriptional activity (14, 27, 42). The interactions of LMP1 CTAR2
with RIP and TRAF6, which serves as an E3 ligase responsible for
the ubiquitination of IRF7 (14, 27), are required for LMP1-in-
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duced activation of IRF7. Recently, we also found that LMP1 can
induce A20-mediated deubiquitination of IRF7, leading to the
transcriptional repression of IRF7 (30). Additional work suggests
that LMP1 may also mediate K48-linked ubiquitination of IRF7,
resulting in its proteasome-mediated degradation (unpublished
data). Together these findings suggest that LMP1 has several
mechanisms by which it modifies IRF7 and regulates its function,
which results in the regulation of cellular immune responses. Fol-
lowing our report that LMP1 induces the sumoylation of cellular
proteins, we initiated studies to determine if IRF7 is a target of
LMP1-induced sumoylation that provides an additional mecha-
nism by which LMP1 can modulate the function of IRF7.
Protein sumoylation is a dynamic and reversible process that
can regulate protein function by altering a protein’s intracellular
location, turnover, ability to interact with other proteins, or ability
to interact with DNA (16, 17, 19). Only 5 to 10% of a protein is in
a sumoylated form at any given time. Sumoylation typically oc-
curs at lysine residues found within the conserved KxE motif,
where  represents a hydrophobic residue (17). Analysis of the
IRF7 protein sequence revealed a putative sumoylation site at po-
sition K452. Recent reports showed that murine IRF7 is sumoy-
lated at K405, which corresponds to K452 of human IRF7, during
vesicular stomatitis virus (VSV) and Ebola Zaire virus infections
(6, 20). In addition, human IRF7 is reported to be sumoylated at
K446 during Sendai virus infection (23). These reports focused on
the sumoylation of IRF7 during RNA virus infections. Here we
explored whether EBV can induce the sumoylation of IRF7 during
latent infection. We propose that LMP1 limits the transcriptional
activity of IRF7 and inhibits induction of innate immune re-
sponses through sumoylation. We have shown that IRF7 is su-
moylated endogenously in type III EBV latency. In addition,
LMP1-induced sumoylation of IRF7 decreases the turnover of
IRF7, resulting in its nuclear accumulation, and limits its tran-
scriptional activity due to the decreased interaction of IRF7 with
the chromatin.
MATERIALS AND METHODS
Cells. Human embryonic kidney (HEK) 293T cells were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) plus 10% fetal bovine
serum (FBS). KR4 cells (a lymphoblastoid cell line representing type III
EBV latency), BL41 EBV wild-type (WT) cells, and BL41 EBV mutant cells
(P3HR1) (4, 5, 7) were maintained in RPMI plus 10% FBS.
Plasmids. Flag-IRF7 and the IFN- promoter construct were gifts
from John Hiscott and have been described previously (24). FLAG-LMP1,
FLAG-LMP1 PQAA, FLAG-LMP1 YIID, and FLAG-LMP1 DM were gifts
from Nancy Raab-Traub (25). FLAG-LMP133bpr (FLAG-LMP1
dCTAR3) was a gift from Wolfgang Hammerschmidt (9).
Luciferase assays. 293T cells were grown in 6-well plates and trans-
fected with 0.6 g of plasmids using polyethylenimine (PEI) (VWR).
Empty vector was used to equalize the total amounts of DNA in the trans-
fections. -Galactosidase served as a transfection control. Luciferase and
-galactosidase assays were performed 24 h posttransfection.
Immunoprecipitation. 293T cells were grown in 100-mm dishes and
transfected with 8 g of DNA using PEI. Forty-eight hours posttransfec-
tion, cells were lysed in NP-40 lysis buffer (50 mM Tris, pH 7.5, 150 mM
NaCl, 1% NP-40, 5 mM dithiothreitol [DTT], 50 M Na3VO4, 100 mM
NaF, 1 mM phenylmethylsulfonyl fluoride [PMSF], 20 M N-ethylma-
leimide [NEM], and complete protease inhibitors; Sigma) or denaturing
lysis buffer (10 mM NaCl, 1.5 mM MgCl2, 10 mM Tris, pH 7.5, 1% SDS,
20 M NEM, benzonase, and complete protease inhibitors). For denatur-
ing immunoprecipitations, cells were incubated at 95°C for 10 min to
denature all proteins. Following lysis, supernatant fluids were collected;
10% was used to examine protein expression and labeled whole-cell ly-
sates (WCL). The remaining 90% was used for immunoprecipitations
where the lysates were incubated with 1 g of antibody for 1 h at 4°C.
Washed protein A/G agarose beads (Santa Cruz) were added to the sam-
ples, which were then incubated overnight at 4°C. Beads were washed four
times with NP-40 lysis buffer. Immunoprecipitations of KR4 cells were
performed in a similar manner with IRF7, SUMO-1, or isotype control
antibodies.
Protein turnover. 293T cells were grown in 6-well plates and trans-
fected using PEI. Cells were treated with cycloheximide (75 g/ml;
Sigma), MG132 (50 M; Sigma), or dimethyl sulfoxide (DMSO) (Sigma)
for 18 h prior to harvesting. Forty-eight hours after transfection, WCLs
were harvested.
Cell compartmentalization. 293T cells were grown and transfected in
100-mm dishes. Forty-eight hours after transfection, cells were harvested,
and cell pellets were processed using the Qproteome cell compartment kit
(Qiagen).
Immunofluorescence microscopy. 293T cells were grown and trans-
fected on glass coverslips. Twenty-four hours after transfection, cells were
fixed with 4% paraformaldehyde. Expression of GFP-IRF7 and that of
DAPI were examined at 100 magnification.
Western blot analysis. WCLs and immunoprecipitants were dena-
tured in sodium dodecyl sulfate (SDS) (Sigma) loading buffer and boiled
for 5 min. The samples were separated by SDS-polyacrylamide gel elec-
trophoresis (SDS-PAGE) and transferred to polyvinylidene fluoride
(PVDF) membranes (GE). Membranes were blocked with 5% milk in
Tris-buffered saline–Tween 20 (TBST) and incubated overnight at 4°C
with primary antibodies. The membranes were washed and incubated
with appropriate horseradish peroxidase-conjugated secondary anti-
bodies for 1 h at room temperature. Membranes were washed again,
and bands were visualized with enhanced chemiluminescence reagent
from GE.
Collecting chromatin fractions. 293T cells were grown and trans-
fected in 100-mm dishes. Cells were harvested 48 h after transfection, and
WCLs and chromatin fractions were collected. As described previously
(15), cells were washed and resuspended in 200 l of CSK buffer (10 mM
PIPES, 100 mM NaCl, 300 mM sucrose, 3 mM MgCl2, 1 mM EGTA, 1 mM
DTT, 0.1 mM ATP, 0.1% Triton X-100, and complete protease inhibitor),
and pellets were collected following centrifugation at 4,000 rpm for 5 min.
Pellets were washed twice with 1 ml CSK buffer, and insoluble pellets were
resuspended in 50 l of 4 SDS sample buffer and boiled for 10 min.
Mutagenesis. GFP-IRF7 k452R was constructed with wild-type GFP-
IRF7 and use of a site-directed mutagenesis kit (Stratagene). Using a for-
ward primer [K452R(F)] (5=-GAG CCT GGT CCT GGT GCG GCT GGA
ACC CTG GCT G-3=) and reverse primer [K452R(R)] (5= CAG CCA
GGG TTC CAG CCG CAC CAG GAC CAG GCT C-3=), PCR was per-
formed. DNA was denatured at 95°C for 30 s, followed by 20 cycles of 95°C
for 30 s, 55°C for 60 s, and 68°C for 9 min. A final elongation step was
performed at 68°C for 10 min. The PCR product was subjected to DpnI
(Stratagene) digestion, transformed into XL-1 supercompetent cells
(Stratagene), and grown on LB-Kan plates. Colonies were selected and
sequenced to verify the mutation of K452. Protein expression was verified
by Western blot analyses.
Semiquantitative RT-PCR. 293T cells were grown and transfected in
100-mm dishes. Cells were collected, and RNA was harvested 24 h after
transfection using the Qiagen RNeasy Plus kit. Total RNA was reverse
transcribed using the ABI Prism RT kit. With the use of the Promega
GoTaq PCR kit and primers for glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) (5=-AGGTGAAGGTCGGAGTCAACG-3= and 5=-AGGG
GTCATTGATGGCAACA-3=) and IFN- (5=-GATTCATCTAGCACTG
GCTGG-3= and 5=-CTTCAGGTAATGCAGAATCC-3=), the cDNA was
amplified by PCR. The cDNA was denatured at 95°C for 30 s, followed by
30 cycles of 95°C for 30 s, 55°C for 60 s, and 68°C for 60 s. PCR products
were fractionated on 2.0% agarose gels and stained with ethidium bro-
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mide, and bands were detected by UV. Relative RNA expression was de-
termined by densitometry.
Antibodies. Anti-FLAG (M2) and antiactin (AG-15) antibodies were
purchased from Sigma. Anti-SUMO-1 (D-11), anti-hemagglutinin (HA)
(F-7), anti-IRF7 (H-246 and G-8), anti-Myc (9E10), anti-histone H1 (AE-
4), anti-EBV Ea-R p85 (6G7), and anti-GAPDH (FL-335) antibodies were
purchased from Santa Cruz. Anti-LMP1 antibodies (CS 1-4) were pur-
chased from Dako. Anti-poly(ADP-ribose) polymerase (PARP) antibod-
ies were from Cell Signaling.
RESULTS
IRF7 is sumoylated endogenously. We recently documented that
LMP1 expression coincides with increased sumoylation of cellular
proteins (2). In this new work, we investigate whether IRF7 could
be specifically targeted for sumoylation by LMP1. Endogenous
sumoylation of IRF7 was examined in EBV-transformed LCLs.
Results from nondenaturing immunoprecipitations showed that
IRF7 and a higher-molecular-mass form of IRF7 (70 kDa, the
predicted size of sumoylated IRF7) were detected when immuno-
precipitations were performed with SUMO-1- or IRF7-specific
antibodies (Fig. 1A). While control antibodies did pull down un-
modified IRF7, the higher-molecular-mass form of IRF7 was not
detected, indicating that this band is specific for SUMO-1 and
IRF7. Immunoprecipitations performed for all SUMO-1-associ-
ated proteins confirmed that higher-molecular-mass forms of
IRF7 could be pulled down with SUMO-1-specific antibodies
(Fig. 1B). These data suggest that IRF7 forms a complex with
SUMO-1 and may be sumoylated during latent EBV infection.
To elucidate whether IRF7 is covalently modified by SUMO-1,
denaturing immunoprecipitations were used to collect all sumoy-
lated proteins. Results revealed a 70-kDa form of IRF7 as well as
higher-molecular-mass forms of IRF7 among the sumoylated
proteins (Fig. 1C). These data demonstrate that IRF7 is covalently
modified endogenously by SUMO-1 during type III EBV latency.
Because we hypothesized that LMP1 induces the sumoylation
of IRF7, we examined the sumoylation of IRF7 in a set of paired
cell lines (BL41 EBV WT, which expresses LMP1, and BL41 EBV
mut [P3HR1], which lacks EBNA2, resulting in no detectable
LMP1 expression) (5, 7, 28). IRF7 expression was not substantial
in either cell line (data not shown); however, endogenous sumoy-
lated IRF7 was consistently detected by immunoprecipitations
(Fig. 1D and E). When all sumoylated proteins were collected,
results showed that increased levels of sumoylated IRF7 were de-
tected in BL41 EBV WT cells compared with levels in BL41 EBV
mut cells (Fig. 1D). Immunoprecipitations performed with IRF7-
specific antibodies and probed for SUMO-1 (Fig. 1E) supported
these findings. Taken together, these data suggest that LMP1 in-
duces the covalent modification of IRF7 by SUMO-1 during latent
EBV infection.
LMP1 induces the sumoylation of IRF7. Next, we further in-
vestigated if LMP1 expression could induce the sumoylation of
IRF7. Denaturing immunoprecipitations to pull down all sumoy-
lated proteins showed that sumoylated IRF7 was detected only
when IRF7, SUMO-1, and LMP1 were coexpressed (Fig. 2A).
Analyses of whole-cell lysates (WCLs) demonstrated that LMP1
mediated the sumoylation of IRF7 with endogenous SUMO-1 and
with FLAG-SUMO-1 (Fig. 2A, lanes 4 and 6). However, only IRF7
FIG 1 IRF7 is sumoylated endogenously in type III EBV LCLs. (A to C) KR4 cells were grown, and cell lysates were collected. (A) Nondenaturing immunopre-
cipitations were performed with SUMO-1, IRF7, or isotype control (anti-EBV EA-R p85) antibodies. Additional nondenaturing (B) or denaturing (C) immu-
noprecipitations were performed with SUMO-1 or isotype control antibodies. Western blot analyses were used to detect IRF7 expression. Duplicate experiments
are shown. (D and E) BL41 EBV WT and BL41 EBV mut cells were grown, and cell lysates were collected. Denaturing immunoprecipitations were performed with
1 mg of cell lysates with SUMO-1, IRF7, or isotype control antibodies. Western blot analyses were used to detect IRF7 or SUMO-1 expression. Duplicate
experiments are represented.
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sumoylated with FLAG-SUMO-1 was detected by immunopre-
cipitation (lane 6).
To confirm that the observed LMP1-induced modification of
IRF7 was in fact by SUMO-1, we used the SUMO protease SENP1,
which differentially cleaves SUMO-1 over SUMO-2 (Fig. 2B) (37,
40). Following denaturing immunoprecipitations to collect all
proteins modified by Myc-SUMO-1, the findings again showed
that sumoylated IRF7 was detected only when LMP1 was coex-
pressed (lane 4). Expression of SENP1 significantly reduced the
levels of sumoylated IRF7 (lane 5), demonstrating that the de-
tected LMP1-induced modification of IRF7 was by SUMO-1. Ad-
ditionally, as the expression of SENP1 increased, the levels of su-
moylated IRF7 decreased (Fig. 2C, lanes 2, 3, and 4), indicating
that IRF7 is desumoylated in a dose-dependent manner. The abil-
ity of additional SUMO proteases to desumoylate IRF7 was also
tested. While SENP1 efficiently cleaves SUMO-1, SENP2 pro-
cesses SUMO-1 less efficiently than SUMO-2 (35). Results showed
that expression of both of these SENPs was able to significantly
reduce LMP1-induced sumoylation of IRF7 (Fig. 2D, lanes 2 and
3). Together, these data demonstrate that LMP1 expression is suf-
ficient to induce the sumoylation of IRF7 and that SENP1 and
SENP2 can serve as SUMO proteases for IRF7.
LMP1-induced sumoylation of IRF7 is dependent on LMP1
CTAR3. Because we previously showed that most of the protein
sumoylation induced by LMP1 can be attributed to LMP1 CTAR3
(2), we examined if CTAR3 was necessary for LMP1-induced su-
moylation of IRF7. We used wild-type LMP1 and LMP1dCTAR3
(LMP133bpr [2, 9]), which lacks LMP1 amino acids 245 to 307,
is unable to interact with the SUMO-conjugating enzyme Ubc9,
and exhibits decreased ability to induce the sumoylation of cellu-
lar proteins (2). Denaturing immunoprecipitations were per-
formed to detect sumoylated IRF7 in the presence of LMP1 and
LMP1dCTAR3. Sumoylated IRF7 was detected with expression
of intact LMP1; however, significantly less sumoylated IRF7
was detected when LMP1dCTAR3 was expressed (Fig. 3A, lane
2 versus lane 3). Densitometry to quantitate levels of sumoy-
lated IRF7 showed a reduction of sumoylated IRF7 (approxi-
mately 80%, as described previously [2]) when LMP1dCTAR3
was expressed in place of LMP1. The magnitude of the decrease
is similar to the reduction of total protein sumoylation pro-
duced by LMP1dCTAR3 (2).
Because IRF7 has been shown to bind indirectly to LMP1
CTAR2 through its interaction with RIP and TRAF6 (14, 27, 39),
we next verified whether LMP1dCTAR3 still interacted with IRF7.
Nondenaturing immunoprecipitations (Fig. 3B) showed that
IRF7 interacted with LMP1dCTAR3 and LMP1. Because LMP1
CTAR2 is intact in LMP1dCTAR3, these data support our previ-
ous observations that CTAR2 is important for the LMP1-IRF7
interaction (14, 27, 39) and demonstrate that LMP1dCTAR3 has a
functional CTAR2 domain.
To investigate whether there is possible cooperation between
LMP1 CTAR3 and CTAR2 in the regulation of IRF7, we analyzed
the sumoylation of IRF7 using several LMP1 mutants. LMP1
PQAA has a nonfunctional CTAR1 domain (Fig. 3C, lane 4),
LMP1 YIID has a nonfunctional CTAR2 domain (lane 5), and
LMP1 DM has nonfunctional CTAR1 and CTAR2 domains (lane
6). We previously documented that these three mutants still inter-
acted with the SUMO-conjugating enzyme Ubc9 (2), so we deter-
mined their effect on the sumoylation of IRF7 (Fig. 3C). The data
showed that, as expected, LMP1 expression coincided with in-
creased sumoylation of IRF7 and that LMP1dCTAR3 abrogated
this effect. Additionally, LMP1 PQAA seemed unimpaired in its
FIG 2 LMP1 expression increases the sumoylation of IRF7. (A) 293T cells were transfected as indicated and cultured for 48 h. Cell lysates were collected, and
denaturing immunoprecipitations were performed with FLAG antibodies. Western blot analyses of the immunoprecipitates and whole-cell lysates (WCL) (2%
of total lysates) were performed for detection of IRF7, sumoylated IRF7, and LMP1. (B) 293T cells were transfected as indicated and cultured for 48 h. Cell lysates
were collected, followed by denaturing immunoprecipitations with c-Myc antibodies. (C and D) 293T cells were transfected as indicated, and WCLs were
collected 48 h posttransfection. Western blot analyses of the immunoprecipitates and WCLs were performed to detect IRF7, sumoylated IRF7, LMP1, SENP1, and
SENP2.
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ability to sumoylate IRF7, whereas neither LMP1 YIDD nor LMP1
DM induced the sumoylation of IRF7. These results suggest that
while CTAR3, the binding site for Ubc9, is necessary for LMP1-
induced sumoylation of IRF7, CTAR2 also contributes to this pro-
cess.
Sumoylated IRF7 accumulates in the nucleus. Next, we ex-
plored the effect of sumoylation on IRF7 function. We have shown
that LMP1-mediated activation of IRF7 coincides with the trans-
location of IRF7 to the nucleus (14, 27, 28, 42, 43), so we investi-
gated the localization of sumoylated IRF7. Findings, both by cell
fractionation and by microscopy, showed that LMP1 expression
increased the nuclear accumulation of IRF7 (Fig. 4A and B). De-
letion of CTAR3 did not affect this response, confirming our find-
ings that LMP1 CTAR2 induces the nuclear accumulation of IRF7
(27, 42). Sumoylated IRF7 also localized to the nucleus (Fig. 4A),
and expression of LMP1dCTAR3 significantly reduced amounts
of modified IRF7 found in the nucleus. Thus, our data demon-
strate that CTAR3 contributes to but is not alone required for the
nuclear accumulation and retention of IRF7. Additionally, these
data demonstrate that sumoylated IRF7 localizes to the nucleus.
Sumoylation promotes the stability of IRF7. Western blot
analyses consistently showed increased amounts of total IRF7
when it was sumoylated compared with nonsumoylated IRF7. Be-
cause sumoylation and ubiquitination both occur at lysine resi-
dues and sumoylation has been shown to protect specific proteins
from proteasomal degradation (16, 19), we investigated if LMP1-
induced sumoylation of IRF7 increased its stability. 293T cells
were transfected and treated with DMSO, cycloheximide (CHX),
or the proteasome inhibitor MG132 for 18 h before harvesting,
and the relative expression of IRF7 was determined (Fig. 5). West-
ern blot analyses showed that CHX treatment resulted in a signif-
icant loss of IRF7 expression (Fig. 5, lane 2; approximately a 75%
decrease) while MG132 treatment greatly increased IRF7 levels
(lane 3; approximate a 250% increase). These data suggest that the
turnover of IRF7 is readily detectable (approximate half-life of 9
h) and that IRF7 is ubiquitinated and undergoes proteasome-me-
diated degradation.
Compared with expression of the vector control, LMP1 expres-
sion coincided with a smaller decrease in IRF7 expression follow-
ing CHX treatment (Lane 8; approximately a 30% decrease) and a
lesser increase in IRF7 levels following MG132 treatment (lane 9).
Coexpression of SUMO-1 with LMP1 abrogated the loss of IRF7
expression produced by CHX. Instead, there was an increase in
IRF7 expression levels (lane 11; approximately 50%), which sug-
gests that sumoylation stabilizes IRF7 expression. Deletion of
CTAR3 yielded results similar to those observed in the absence of
LMP1 expression. CHX treatment resulted in the loss of IRF7
expression, and MG132 treatment increased IRF7 expression re-
gardless of whether SUMO-1 was overexpressed.
Together, these data demonstrate that sumoylation of IRF7
promotes the stability of IRF7, decreasing its turnover rate. Addi-
tionally, the findings suggest that IRF7 is targeted for proteasomal
degradation. Finally, sumoylation decreases its proteasomal deg-
radation, which suggests that there is competition between the
ubiquitination and sumoylation of IRF7.
LMP1-induced IRF7 sumoylation limits its transcriptional
activity. Next we investigated effects of sumoylation on the
transcriptional activity of IRF7. IRF7 binds to and activates
ISREs (14, 27, 42, 44, 45), and we studied the activation of
ISRE-luciferase constructs when IRF7 was sumoylated. Lucif-
erase and -gal assays were performed 24 h after transfection.
Luciferase expression was normalized to -gal expression, and
fold changes in promoter activity were determined. LMP1 ex-
pression significantly (P 	 0.05) increased the ability of IRF7 to
bind to and activate ISREs (Fig. 6A), confirming our previous
data (42). Deletion of CTAR3 significantly (P 	 0.05) increased
the transcriptional activity of IRF7 compared to that when
wild-type LMP1 was expressed. When SUMO-1 was coex-
pressed with LMP1 to increase the sumoylation of IRF7, a sig-
nificant (P 	 0.05) decrease in IRF7 transcriptional activity was
observed. However, no effects on activity were observed when
SUMO-1 was coexpressed with LMP1dCTAR3.
To confirm that the changes in IRF7 transcriptional activity were
due to effects of SUMO-1, we used the SUMO protease SENP1 in
parallel experiments (Fig. 6B). Confirming our earlier data, we found
that when SUMO-1 was overexpressed, LMP1dCTAR3 significantly
(P 	 0.05) increased the transcriptional activity of IRF7 compared
with that with LMP1. Overexpression of SENP1 significantly (P 	
FIG 3 LMP1-induced sumoylation of IRF7 is dependent on CTAR3. (A) 293T
cells were transfected as indicated and cultured for 48 h. Cell lysates were
collected, and denaturing immunoprecipitations were performed with c-Myc
antibodies. Western blot analyses of the immunoprecipitates and WCLs were
used to detect IRF7, sumoylated IRF7, and LMP1. (B) 293T cells were trans-
fected as indicated and cultured for 48 h. Cell lysates were collected, and non-
denaturing immunoprecipitations were performed with FLAG antibodies, fol-
lowed by Western blot analyses as described above. (C) 293T cells were
transfected with GFP-IRF7, Myc–SUMO-1, and the indicated FLAG-LMP1
constructs. Cell lysates were collected 48 h posttransfection, and Western blot
analyses were used to detect IRF7, sumoylated IRF7, and LMP1. Actin served
as a loading control.
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0.05) increased the ability of LMP1 to induce the transcriptional
activity of IRF7 but did not affect the activation of IRF7 by
LMP1dCTAR3.
Additional support for the hypothesis that LMP1-induced su-
moylation limits the activation of IRF7 was obtained by examin-
ing the levels of IFN- mRNA in transiently transfected 293T cells.
Relative IFN- mRNA expression was normalized to relative
GAPDH mRNA expression, and fold changes in IFN- mRNA
levels were calculated (Fig. 6C). The findings were similar to re-
sults of reporter assays in that LMP1 expression significantly (P 	
0.05) increased IFN- mRNA levels, and deletion of CTAR3 pro-
duced even higher levels of IFN- mRNA. Overexpression of
SUMO-1 significantly (P 	 0.05) decreased the ability of LMP1 to
induce IFN- mRNA expression in the presence of IRF7 but had
FIG 4 LMP1-induced sumoylated IRF7 localizes to the nucleus. (A) 293T cells were transfected with FLAG-LMP1 or FLAG-LMP1dCTAR3 along with
GFP-IRF7, Myc–SUMO-1, or the vector control and cultured for 48 h. Cytoplasmic (CE) and nuclear (NE) extracts were collected, and Western blot analyses
were performed for detection of IRF7, sumoylated IRF7, and LMP1. PARP and GAPDH were used as loading controls. (B) 293T cells were transfected with
FLAG-LMP1 or FLAG-LMP1dCTAR3 along with GFP-IRF7 or the vector control and cultured for 24 h. Cells were fixed and examined by immunofluorescence
microscopy (magnification, 100).
FIG 5 LMP1-induced sumoylation of IRF7 inhibits IRF7 turnover. 293T cells were transfected as indicated, and 18 h before harvesting, cells were treated with DMSO,
cycloheximide (CHX) (75 g/ml), or MG132 (50 M). Cell lysates were harvested 48 h posttransfection and immunoblotted to determine IRF7 and LMP1 levels. Actin
was used as a loading control. Densitometry was used to determine relative protein levels (normalized to actin). Data are shown as means 
 SD.
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no such effect with LMP1 dCTAR3. Taken together, these data
demonstrate that LMP1-induced sumoylation of IRF7 limits or
modulates the transcriptional activity of IRF7. These findings sug-
gest that CTAR3 may serve as a negative regulatory domain for
LMP1-induced activation of IRF7.
LMP1-induced sumoylation of IRF7 inhibits its ability to as-
sociate with chromatin. Because we observed that sumoylation
limits the transcriptional activity of IRF7, we next investigated
whether this regulation was due to the loss in the ability of sumoy-
lated IRF7 to associate with chromatin. Chromatin fractions were
collected from transfected cells (15), and fold changes in relative
IRF7 expression in the fractions (normalized to total IRF7 expres-
sion) were determined. Results showed that LMP1 expression sig-
nificantly (P 	 0.05) increased the association of IRF7 with chro-
matin, but coexpression of SUMO-1, which increased the
sumoylation of IRF7, significantly (P 	 0.05) decreased the asso-
ciation of IRF7 with the chromatin fractions (Fig. 7A). The asso-
ciation of IRF7 with the chromatin fractions remained signifi-
cantly (P 	 0.05) increased when LMP1dCTAR3 was expressed,
regardless of SUMO-1 overexpression. SENP1 expression abro-
gated the effects of SUMO on LMP1-induced IRF7 association
with the chromatin (Fig. 7B), but SENP1 did not affect the asso-
ciation of IRF7 with the chromatin induced by LMP1dCTAR3.
Together, these data suggest that LMP1 CTAR3-induced sumoy-
lation of IRF7 inhibits its ability to interact with DNA.
LMP1 modifies IRF7 by SUMO-1 at lysine 452. Finally, we
investigated the residue of IRF7 modified by SUMO-1 with
expression of LMP1. Analysis of the IRF7 sequence using the
SUMOplot software program (Abgent) revealed three putative
sumoylation sites: K452, which has a high probability of being
sumoylated, and K179 and K45, which have low probabilities of
being sumoylated. We mutated K452 to abolish the SUMO motif
(KxE ¡ RxE) and examined its ability to be sumoylated by
LMP1 (Fig. 8). Denaturing immunoprecipitations were per-
formed for all sumoylated proteins. Results revealed that while
LMP1 could induce the sumoylation of wild-type IRF7, IRF7
K452R was not detected in the sumoylated proteins.
To verify that LMP1-induced sumoylation of IRF7 limits its
function, we examined the localization, stability, transcriptional
activity, and chromatin association of the sumoylation-defective
IRF7 K452R protein. As expected, LMP1 expression could still
induce the nuclear accumulation of IRF7 K452R (Fig. 8B), dem-
onstrating that sumoylation does not affect the localization of
IRF7. Experiments with cells treated with cycloheximide or
DMSO revealed that mutation of IRF7 K452 abrogated LMP1-
and SUMO-induced stability of IRF7 (Fig. 8C), supporting our
suggestion that LMP1-mediated sumoylation of IRF7 reduces the
turnover of IRF7. Reporter assays confirmed that LMP1-mediated
sumoylation of IRF7 limits its transcriptional activity (Fig. 8D).
Specifically, while LMP1-mediated sumoylation of wild-type IRF7
significantly (P 	 0.05) limited the ability of IRF7 to activate
ISREs, it had no effect on the SUMO-deficient IRF7 K452R. The
data showed that in addition to abrogating the repressive effect on
the transcriptional activity, mutation of IRF7 K452 also reversed
the inhibitory effect that sumoylation had on LMP1-induced as-
sociation of IRF7 with chromatin (Fig. 8E). LMP1 expression in-
creased the association of both wild-type IRF7 and IRF7 K452R
with the chromatin, confirming our earlier findings. However,
while LMP1-induced sumoylation inhibited the association of
wild-type IRF7 with the chromatin, it had no effect on IRF7
K452R. Taken together, these data suggest that LMP1 induces the
sumoylation of IRF7 at K452, which inhibits IRF7 turnover and
limits the ability of IRF7 to bind to DNA and to act as a transcrip-
tion factor during latent EBV infection.
DISCUSSION
We recently documented that LMP1 interacts with the SUMO-
conjugating enzyme Ubc9 and induces the sumoylation of cellular
FIG 6 LMP1-induced sumoylation of IRF7 limits its transcriptional activity.
(A and B) 293T cells were transfected as indicated along with ISRE-luciferase
and beta-galactosidase and assayed 24 h posttransfection. Firefly luciferase
activity was normalized to beta-galactosidase expression, and fold changes in
ISRE activity were calculated. Data are shown as means 
 SD. (C) 293T cells
were transfected as indicated, and total RNA was harvested 24 h posttransfec-
tion. RT-PCR was carried out to determine IFN- and GAPDH mRNA levels,
and fold changes in IFN- expression (relative to GADPH expression) were
determined. Data are shown as means 
 SD.
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proteins (2). In addition, we have shown that LMP1 can activate
IRF7 by both phosphorylation and ubiquitination (14, 27, 42). We
now identify IRF7 as a primary target for LMP1-induced sumoy-
lation. Reports on the sumoylation of IRFs are limited, and to
date, they all show that sumoylation of IRF family members re-
presses their transcriptional activity (18, 20, 21, 26). Of the three
reports of IRF7 sumoylation during RNA viral infections (6, 20,
23), two document that murine IRF7 is sumoylated at K405, which
corresponds to human K452. These reports show that during vesic-
ular stomatitis virus (VSV) and Ebola virus infections, IRF7 is sumoy-
lated, resulting in the inhibition of a type I IFN response (20). The
third report showed that IRF7 is sumoylated at K446 by TRIM28
during Sendai virus infection (23). We have documented that in ad-
dition to K452, K444 and K446 are critical for LMP1-mediated K63-
linked ubiquitination of IRF7 (6, 20, 23). Accordingly, whether LMP1
could also sumoylate IRF7 at one of these residues and limit its activ-
ity was of considerable interest. Our data show that LMP1 can in fact
induce the sumoylation of IRF7 at K452.
In addition to the overexpression studies, we documented by
both denaturing and nondenaturing immunoprecipitations that
IRF7 was sumoylated endogenously. Denaturing immunoprecipi-
tations revealed that IRF7 is covalently modified by SUMO-1.
Nondenaturing immunoprecipitations were performed in the
presence of the SUMO protease inhibitor N-ethylmaleimide,
which covalently modified the catalytic cysteine residue of the
SUMO proteases. This modification enabled examination of
both the sumoylation of IRF7 and the interaction of IRF7 with
SUMO-1. The results suggested that IRF7 both interacts with and
is modified by SUMO-1. A consensus SUMO-interacting motif
has been identified (V/I/L-x-V/I/L-V/I/L or V/I/L-V/I/L-x-V/I/L,
where x is any amino acid) (10, 38). Analysis of the IRF7 sequence
revealed that it contains a SUMO-interacting motif between
amino acids 448 and 451, adjacent to the residue covalently mod-
ified by SUMO-1 (K452). Because we previously reported that
LMP1 dysregulates sumoylation processes within the cell, increas-
ing overall levels of sumoylated proteins (2), it is possible that
LMP1 has two mechanisms by which it negatively regulates the
function of IRF7: (i) by the covalent modification of IRF7 by
SUMO-1 and (ii) by increasing the interaction of IRF7 with
SUMO-1. Here we have shown how the covalent modification of
IRF7 by SUMO-1 affects its function.
LMP1-induced sumoylation of IRF7 was dependent on LMP1
CTAR3, and we have shown, for the first time, that there is coop-
eration between LMP1 CTAR2 and LMP1 CTAR3 in the regula-
tion of a target protein, specifically IRF7. Previous studies have
focused on the role of CTAR2 in inducing the phosphorylation,
K63-linked ubiquitination, and A20-mediated deubiquitination
of IRF7 (27, 30). Here, we identified a novel role for LMP1 CTAR3
in the regulation of IRF7, specifically in the sumoylation of IRF7,
which is mediated by the binding of Ubc9 to CTAR3. Our findings
show that while a functional CTAR2 domain is still required for
CTAR3-induced sumoylation of IRF7, these findings could result
from the loss of the LMP1-IRF7 interaction upon mutation of
CTAR2. The importance of CTAR2 for the LMP1-IRF7 interac-
tion is compounded by the observations that CTAR3 did not ab-
rogate the LMP1-IRF7 interaction. Together, these findings ex-
pose a new area of IRF7 regulation that warrants further
examination (i.e., cooperation or competition between CTAR2
and CTAR3 in the regulation of IRF7).
The expression of the cellular SUMO protease SENP1 (as well
as SENP2 and SENP5; data not shown) could reverse the effects of
LMP1 CTAR3-induced sumoylation of IRF7. SENP1 is involved
in SUMO maturation, or the initial processing of immature
SUMO to generate a C-terminal diglycine motif (37, 40). Addition-
ally, SENP1 can deconjugate SUMO-1, SUMO-2, and SUMO-3 from
the target protein, resulting in protein desumoylation. SENP1 can
itself be covalently modified by SUMO-1 (1); however, the functional
consequence of SENP1 sumoylation remains unknown. We found
that in the presence of LMP1, sumoylated SENP1 could be detected
by immunoprecipitation and Western blot analyses of whole-cell ly-
sates. Whether LMP1-induced sumoylation of SENP1 has a role in
LMP1 CTAR3-induced sumoylation of cellular proteins remains un-
examined. However, it is possible that sumoylation of SENP1 by
LMP1 is a second mechanism through which the viral oncoprotein
hijacks the cellular SUMO machinery during latent EBV infection.
In addition to identifying the IRF7 residue modified by
SUMO1 and the LMP1 requirements for sumoylation of IRF7, we
also document the effects of sumoylation on IRF7 function. While
sumoylation did not alter LMP1-induced nuclear translocation of
IRF7, sumoylated IRF7 was detected in the nuclear fractions and
not the cytoplasmic extracts, suggesting that sumoylation may act
to retain IRF7 in the nucleus. Because the putative nuclear export
FIG 7 LMP1-induced sumoylation of IRF7 inhibits its association with chromatin. (A and B) 293T cells were transfected as indicated. WCLs and chromatin
fractions were collected 48 h posttransfection (15), and Western blot analyses were used to detect IRF7 expression. Densitometry was performed, and IRF7
expression in the chromatin fractions was normalized to IRF7 expression in the WCLs. Fold changes in IRF7 chromatin association were determined. Data are
shown as means 
 SD.
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signal of IRF7 is located within amino acids 416 to 467 (24) and we
identified K452 as the primary site of sumoylation, LMP1-in-
duced sumoylation of IRF7 possibly blocks the nuclear export of
IRF7, thus helping retain it within the nucleus.
Regardless of its localization, our data show that turnover of
IRF7 is inhibited by sumoylation. IRF7 is targeted by K48-linked
ubiquitination for proteasome-mediated degradation (41), and
both ubiquitination, K48-linked and K63-linked, and sumoyla-
tion occur at lysine residues, which results in competition between
different posttranslational modifications. Our previous results
suggest that LMP1 induces the K63-linked ubiquitination of IRF7
(14, 27, 30). Here our data suggest that LMP1 also targets IRF7 for
K48-linked ubiquitination, which leads to its proteasomal degra-
dation during latent EBV infection. We now show that sumoyla-
tion may compete with ubiquitination at K452 in regulating IRF7
function and expression. This competition would result in in-
creased accumulation of IRF7 within the cell, which would add to
the increased expression of IRF7 induced by LMP1 (42). Thus,
increases in transcription of the irf7 gene along with decreases in
protein degradation together result in the increased levels of IRF7
observed in latently infected cells.
Although sumoylation of IRF7 resulted in increased nuclear
retention and stability of the protein, it had a negative effect on the
ability of IRF7 to interact with the chromatin and activate pro-
moters. While the activation of ISRE reporters and the association
of IRF7 with the chromatin were significantly higher when LMP1
was coexpressed than with the vector control, these levels were
even greater with expression of SENP1 or LMP1dCTAR3 due to
the loss of IRF7 sumoylation. These findings confirm and explain
the previous reports of the negative effect of sumoylation on IRF7
FIG 8 LMP1-induced sumoylation of IRF7 occurs at IRF7 lysine 452. 293T cells were transfected as indicated. (A) Cell lysates were collected 48 h posttransfec-
tion. Denaturing immunoprecipitations were performed with c-Myc antibodies. Western blot analyses were performed on the immunoprecipitants and
whole-cell lysates to determine IRF7, sumoylated IRF7, IRF7 K452R, sumoylated IRF7 K452R, and LMP1 expression. (B) Cytoplasmic (CE) and nuclear (NE)
extracts were collected, and Western blot analyses were used to detect IRF7 K452R and LMP1. Histone H1 and GAPDH were used as loading controls. (C)
Eighteen hours before harvesting, cells were treated with DMSO or CHX (75 g/ml). Cell lysates were harvested 48 h posttransfection and immunoblotted to
determine IRF7/IRF7 K452R and actin levels. Densitometry was used to determine relative protein levels, and the fold change in relative IRF7/IRF7 K452R
expression was determined. (D) Reporter assays were performed as described for Fig. 6. (E) WCLs and chromatin fractions were collected, and fold changes in
IRF7 chromatin association were determined as described for Fig. 7. Data are shown as the means 
 SD.
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transcriptional activity (29, 30) and suggest that sumoylation of
IRF7 inhibits its ability to interact with DNA, thus repressing its
transcriptional activity.
In summary, our studies of the regulation of IRF7 by LMP1
document that LMP1, in addition to phosphorylating IRF7, can
induce the following modifications of IRF7: (i) the K63-linked
ubiquitination of IRF7 (27), resulting in its transcriptional activa-
tion, (ii) the A20-mediated deubiquitination of IRF7 (30), result-
ing in its transcriptional repression, and (iii) the sumoylation of
IRF7, limiting its activity. Thus, LMP1 tightly modulates the in-
duction of innate immune responses during latent EBV infection.
We propose that during latent EBV infections there is a balance
between the ubiquitination, deubiquitination, and sumoylation
status of IRF7. This balance regulates both the activation and re-
pression of IRF7 function and transcriptional activity. Therefore,
if an innate immune response is involved, LMP1 can signal the
K63-linked ubiquitination of IRF7, leading to the activation of
ISREs. When the need for an immune response wanes, LMP1,
acting through A20, induces the deubiquitination of IRF7, and
through its interaction with Ubc9 via CTAR3, LMP1 can then
induce the sumoylation of IRF7, limiting the activation of ISREs
yet protecting IRF7 from degradation in case the need for an im-
mune response arises. This delicate balance, between the activa-
tion and repression of IRF7, may be beneficial for the maintenance
of viral latency, and disruption of this balance may amplify the
oncogenic potential of LMP1. Therefore, deciphering mecha-
nisms by which LMP1 both activates and represses the functions
of IRF7 may help elucidate ways by which this viral oncoprotein
may be manipulated to yield the required outcome.
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